Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(7):944–952. doi: 10.1054/bjoc.2001.2030

A prognostic model for ovarian cancer

T G Clark 1, M E Stewart 2, D G Altman 1, H Gabra 2, J F Smyth 2
PMCID: PMC2375096  PMID: 11592763

Abstract

About 6000 women in the United Kingdom develop ovarian cancer each year and about two-thirds of the women will die from the disease. Establishing the prognosis of a woman with ovarian cancer is an important part of her evaluation and treatment. Prognostic models and indices in ovarian cancer should be developed using large databases and, ideally, with complete information on both prognostic indicators and long-term outcome. We developed a prognostic model using Cox regression and multiple imputation from 1189 primary cases of epithelial ovarian cancer (with median follow-up of 4.6 years). We found that the significant (P≤ 0.05) prognostic factors for overall survival were age at diagnosis, FIGO stage, grade of tumour, histology (mixed mesodermal, clear cell and endometrioid versus serous papillary), the presence or absence of ascites, albumin, alkaline phosphatase, performance status on the ZUBROD-ECOG-WHO scale, and debulking of the tumour. This model is consistent with other models in the ovarian cancer literature; it has better predictive ability and, after simplification and validation, could be used in clinical practice. http://www.bjcancer.com © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: ovarian cancer, prognostic model, overall survival

Full Text

The Full Text of this article is available as a PDF (97.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Dahlberg S., Green S. J., Garcia D., Hannigan E. V., O'Toole R., Stock-Novack D., Surwit E. A., Malviya V. K., Jolles C. J. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993 Jan 15;71(2 Suppl):618–627. doi: 10.1002/cncr.2820710220. [DOI] [PubMed] [Google Scholar]
  2. Altman D. G., Royston P. What do we mean by validating a prognostic model? Stat Med. 2000 Feb 29;19(4):453–473. doi: 10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  3. Ansell S. M., Rapoport B. L., Falkson G., Raats J. I., Moeken C. M. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol. 1993 Aug;50(2):215–220. doi: 10.1006/gyno.1993.1195. [DOI] [PubMed] [Google Scholar]
  4. Brinkhuis M., Baak J. P., Meijer G. A., van Diest P. J., Mogensen O., Bichel P., Neijt J. P. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. J Clin Pathol. 1996 Feb;49(2):142–148. doi: 10.1136/jcp.49.2.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brun J. L., Feyler A., Chêne G., Saurel J., Brun G., Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000 Jul;78(1):21–27. doi: 10.1006/gyno.2000.5805. [DOI] [PubMed] [Google Scholar]
  6. Carey M.S., Dembo A.J., Simm J.E., Fyles A.W., Treger T., Bush R.S. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer. 1993 Jan;3(1):24–35. doi: 10.1046/j.1525-1438.1993.03010024.x. [DOI] [PubMed] [Google Scholar]
  7. Dembo A. J., Bush R. S., Brown T. C. Clinico-pathological correlates in ovarian cancer. Bull Cancer. 1982;69(3):292–297. [PubMed] [Google Scholar]
  8. Greenland S., Finkle W. D. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995 Dec 15;142(12):1255–1264. doi: 10.1093/oxfordjournals.aje.a117592. [DOI] [PubMed] [Google Scholar]
  9. Harrell F. E., Jr, Lee K. L., Mark D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996 Feb 28;15(4):361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  10. Hartmann L. C., Podratz K. C., Keeney G. L., Kamel N. A., Edmonson J. H., Grill J. P., Su J. Q., Katzmann J. A., Roche P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994 Jan;12(1):64–69. doi: 10.1200/JCO.1994.12.1.64. [DOI] [PubMed] [Google Scholar]
  11. Högberg T., Carstensen J., Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol. 1993 Jan;48(1):38–49. doi: 10.1006/gyno.1993.1007. [DOI] [PubMed] [Google Scholar]
  12. Junor E. J., Hole D. J., McNulty L., Mason M., Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999 Nov;106(11):1130–1136. doi: 10.1111/j.1471-0528.1999.tb08137.x. [DOI] [PubMed] [Google Scholar]
  13. Kappen H. J., Neijt J. P. Advanced ovarian cancer. Neural network analysis to predict treatment outcome. Ann Oncol. 1993;4 (Suppl 4):31–34. doi: 10.1093/annonc/4.suppl_4.s31. [DOI] [PubMed] [Google Scholar]
  14. Kehoe S., Powell J., Wilson S., Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer. 1994 Nov;70(5):1014–1017. doi: 10.1038/bjc.1994.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kosary C. L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994 Jan-Feb;10(1):31–46. doi: 10.1002/ssu.2980100107. [DOI] [PubMed] [Google Scholar]
  16. Lubsen J., Pool J., van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med. 1978 Apr;17(2):127–129. [PubMed] [Google Scholar]
  17. Lund B., Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol. 1991 Apr;2(4):281–287. doi: 10.1093/oxfordjournals.annonc.a057937. [DOI] [PubMed] [Google Scholar]
  18. Lund B., Williamson P., van Houwelingen H. C., Neijt J. P. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res. 1990 Aug 1;50(15):4626–4629. [PubMed] [Google Scholar]
  19. Makar A. P., Baekelandt M., Tropé C. G., Kristensen G. B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995 Feb;56(2):175–180. doi: 10.1006/gyno.1995.1027. [DOI] [PubMed] [Google Scholar]
  20. Marsoni S., Torri V., Valsecchi M. G., Belloni C., Bianchi U., Bolis G., Bonazzi C., Colombo N., Epis A., Favalli G. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer. 1990 Sep;62(3):444–450. doi: 10.1038/bjc.1990.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marx D., Meden H., Brune T., Kron M., Korabiowska M., Kuhn W., Schauer A. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res. 1997 Jan-Feb;17(1B):775–780. [PubMed] [Google Scholar]
  22. Meden H., Marx D., Raab T., Kron M., Schauer A., Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol (Tokyo 1995) 1995 Apr;21(2):167–178. doi: 10.1111/j.1447-0756.1995.tb01090.x. [DOI] [PubMed] [Google Scholar]
  23. Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995 Aug;86(2):259–264. doi: 10.1016/0029-7844(95)00126-c. [DOI] [PubMed] [Google Scholar]
  24. Peters-Engl C., Obermair A., Heinzl H., Buxbaum P., Sevelda P., Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999 Oct;81(4):662–666. doi: 10.1038/sj.bjc.6690744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Swenerton K. D., Hislop T. G., Spinelli J., LeRiche J. C., Yang N., Boyes D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985 Feb;65(2):264–270. [PubMed] [Google Scholar]
  26. Warwick J., Kehoe S., Earl H., Luesley D., Redman C., Chan K. K. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer. 1995 Dec;72(6):1513–1517. doi: 10.1038/bjc.1995.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. van Buuren S., Boshuizen H. C., Knook D. L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999 Mar 30;18(6):681–694. doi: 10.1002/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  28. van Houwelingen J. C., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Neijt J. P. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 1989 Jun;7(6):769–773. doi: 10.1200/JCO.1989.7.6.769. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES